MEDEZE Wins Frost & Sullivan’s 2025 Southeast Asia Company Award

MEDEZE Group Public Company Limited has received the prestigious 2025 Southeast Asia Company of the Year Recognition from Frost & Sullivan for its exceptional contributions to the stem cell banking and regenerative medicine sector. This accolade, announced on December 15, 2025, underscores MEDEZE’s commitment to innovation, regulatory excellence, and clinical alignment in transforming healthcare across Southeast Asia.

Frost & Sullivan’s recognition is based on a comprehensive evaluation process that looks at both strategic effectiveness and execution. MEDEZE distinguished itself by aligning its strategic initiatives with market demands while executing them efficiently. According to Unmesh Lal, Vice President of Healthcare & Life Sciences at Frost & Sullivan, “MEDEZE is redefining stem cell banking in Southeast Asia through full-spectrum, clinically aligned solutions.”

The company’s long-term strategy focuses on innovation, clinical readiness, and international expansion. MEDEZE has established one of the most advanced cell banking ecosystems in the region, covering the entire spectrum from biological material collection to clinical application. This vertically integrated approach ensures high-quality standards and compliance across various markets.

Central to MEDEZE’s success is its emphasis on innovation. The company employs proprietary technologies, such as the AutoXpress System for automated cord blood processing and the Chibuya Robotic Stem Cell Culture System, the first of its kind to offer full-room cleanroom automation. These advancements enable MEDEZE to manufacture therapeutic-grade products at scale. Additionally, its AI-powered Hair Follicle Restoration platform and exclusive diagnostic technologies from Japan highlight MEDEZE’s capability to expand cell applications into both clinical and aesthetic domains.

MEDEZE’s commitment to quality is further exemplified by its recognition as the only Thai stem cell bank accredited by the US-based Association for the Advancement of Blood & Biotherapies (AABB). It also holds ISO 9001 and ISO 22716 certifications, demonstrating compliance with the highest safety and quality standards.

The company collaborates with over 260 hospital partners, including prominent institutions like Samitivej Hospital Group and Bangkok Hospital. MEDEZE plays a significant role in Thailand’s ADMP Sandbox clinical program, which includes ongoing trials for various conditions such as osteoarthritis and colorectal cancer. With these initiatives, MEDEZE aims to be among the first private entities in Southeast Asia to commercialize licensed cell therapies by 2026.

Frost & Sullivan’s annual award celebrates organizations that excel in strategy development and execution, leading to noteworthy improvements in market share and customer satisfaction. MEDEZE’s integrated operational model and commitment to sustainable growth underscore its leadership in biotechnology, positioning the company at the forefront of Southeast Asia’s shift toward licensed regenerative therapies.

This recognition serves to highlight MEDEZE’s role as a transformative force in the healthcare landscape, setting new industry standards through its innovative practices and operational excellence.